Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takeda Applies for Mutual Agreement Procedure to Resolve Double Taxation
July 21, 2008
- OHARA Aims at Sales of \700 Mil. with Amlodipine Generics in FY2009
July 21, 2008
- Ain Pharmaciez to Achieve 90% Price Agreement Rate by End of July
July 21, 2008
- Korosho Tests Purity of Generics of 10 APIs
July 21, 2008
- Korosho to Investigate Price Agreement Rate as of End of June
July 21, 2008
- R&D NEWS IN BRIEF
July 21, 2008
- Ranbaxy Categorically Denies Allegations
July 21, 2008
- Korosho Gives Up Development of 2 Unapproved Drugs
July 21, 2008
- Nippon Kayaku to Actively Invest in Macromolecular Anticancer Agents
July 21, 2008
- Korosho Calls For Commercialization of Cures of Alzheimer's Disease in 10 Years
July 21, 2008
- Ferring Accelerates Business Development in Japan Aiming at \30 Bil. Sales in 2017
July 21, 2008
- Daiichi Sankyo to Collaborate with Seattle Genetics to Develop ADC Drugs
July 21, 2008
- Daiichi Sankyo Enters \88 Bil. Market for NSAID Tapes with Loxonin
July 21, 2008
- Traditional Business Model Seeing the End Coming: Mr Makov
July 14, 2008
- OPINION
July 14, 2008
- Nihon Chouzai Settles Prices with All Wholesalers by End of June
July 14, 2008
- Treatment with Erbitux Requires KRAS Gene Testing to Predict Efficacy
July 14, 2008
- BUSINESS NEWS IN BRIEF
July 14, 2008
- Biologics Provide a New Approach to RA Treatment in Japan
July 14, 2008
- Avapro Leaps to Top Position in May: Rep Track Survey
July 14, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…